BICILLIN C-R (penicillin g benzathine and penicillin g procaine) by Pfizer is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections, the treatment of the following in pediatric patients: moderately severe to severe infections of the upper-respiratory tract, scarlet fever and 3 more indications. First approved in 1953.
Drug data last refreshed 36m ago · AI intelligence enriched 6d ago
BICILLIN C-R is a combination injectable antibiotic containing penicillin G benzathine and penicillin G procaine, approved in 1953. It treats moderately severe to severe infections including upper-respiratory tract infections, scarlet fever, erysipelas, and skin/soft-tissue infections caused by susceptible streptococci, primarily in pediatric patients. The drug works by inhibiting bacterial cell wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable and causing bacterial death.
This legacy antibiotic faces steep LOE with minimal commercial infrastructure; teams are typically small and focused on compliance and supply continuity rather than growth.
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable resulting in death of the…
Worked on BICILLIN C-R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BICILLIN C-R offers minimal growth potential and a narrowing job market (0 linked openings); roles center on managing a declining franchise, ensuring regulatory compliance, and optimizing manufacturing efficiency. Career advancement on this product is constrained; lateral moves to growth-stage antibiotics or adjacent franchises are strategically prudent.